July 19 (Reuters) - Merck & Co on Thursday announced price cuts to some of its medicines, including a 60 percent reduction to a little-used hepatitis C treatment, after U.S. President Donald Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.
Amid heightened public and political scrutiny over the high cost of prescription medicines and promises by Trump that drug price reductions were coming, New Jersey-based Merck became the first major drugmaker to announce voluntary price decreases.
In addition to slashing the price of Zepatier for hepatitis C, Merck said it would lower the list price of six other older drugs by 10 percent. It also said it would not increase the average net price of other medicines in its portfolio of products by more than the inflation rate annually.
Merck’s most important product, the cancer drug Keytruda, lists for about $150,000 a year.
Trump, who has vowed to help reduce the cost of prescription drugs to consumers, had expressed anger at drugmakers over planned price hikes. In a tweet on July 9, he said they “should be ashamed” and that his administration would respond.
Under direct pressure from Trump, Pfizer Inc, the largest U.S. drugmaker, said it would delay July 1 price increases until the end of the year or until the president’s blueprint for lowering drug costs goes into effect.
Swiss drugmaker Novartis followed this week, saying it would not raise prices in the United States for the rest of the year.
Although Pfizer and Novartis only promised delays to price hikes, Trump said they decided to not increase prices. He has not yet commented on Merck’s announcement.
“This decision (by Merck) is a response to President Trump’s blueprint and reflects the industry’s understanding that the President is serious about bringing change to our drug markets,” U.S. Health and Human Services Secretary Alex Azar said in a statement.
Trump made lowering prescription drug prices a top 2016 presidential campaign issue.
In May, Trump unveiled a “blueprint” to lower drug prices that appeared to largely spare drugmakers and instead took aim at “middlemen,” such as health insurers and pharmacy benefits managers, which demand hefty rebates in exchange for broad access to patients. Pharmaceutical company stocks rose after the blueprint was announced.
The cost of healthcare is expected to be a major campaign issue ahead of November midterm elections, with control of both the House of Representatives and the Senate, both currently controlled by Trump’s fellow Republicans, potentially up for grabs. (Reporting By Yasmeen Abutaleb Editing by Bill Berkrot)